Skip to main content
. 2023 Jul 10;120(29):e2303740120. doi: 10.1073/pnas.2303740120

Fig. 2.

Fig. 2.

Elevation of ANG2 in RAS mutant tumors. (A) mRNA expression of Angpt2 and Pdgfb in T241-vector, T241-HRAS mutant, and T241-KRAS mutant tumors (n = 4 biological samples per group). (B) Tumor microvessels (red) and pericytes (green) in T241-KRAS mutant tumors treated with vehicle, an anti-ANG2 neutralizing antibody, and an anti-PDGFRβ neutralizing antibody. Quantification of microvessel density and vascular coverage by pericytes (n = 10 random fields per group). Arrowheads indicate vessel-associated pericytes. (Scale bar, 50 μm.) (C and D) ANGPT2 mRNA expression and ANG2 protein levels in BxPC3 WT and BxPC3 KRAS mutant PDAC tumors (C) and HCT116 KRAS mutant and HCT116 shKRAS CRC tumors (D) (n = 2 to 4 biological samples per group). (E–G) ANGPT2 mRNA expression and ANG2 protein levels in BxPC3 and PANC1 PDAC tumors (E), HT29 and HCT116 CRC tumors (F), and Calu-3 and A549 lung tumors (G) (n = 2 to 3 biological samples per group). All data represent mean ± SEM. (Scale bar, 50 μm.) Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison tests (A and B) and two-sided unpaired t tests (C–G). *P < 0.05, **P < 0.01, ***P < 0.001. N.S., not significant. PDAC, pancreatic ductal adenocarcinoma; CRC, colorectal carcinoma; LC, lung cancer.